Notwithstanding positive clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. Such insurers are https://minaentg478500.blogchaat.com/42318094/copyright-s-drug-faces-is-encountering-pbm-obstacles-a-look-at-access-battles